Senzime (STO:SEZI) Full Year 2024 Results
Key Financial Results
- Revenue: kr58.5m (up 64% from FY 2023).
- Net loss: kr118.7m (loss narrowed by 12% from FY 2023).
- kr0.99 loss per share (improved from kr1.45 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Senzime Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 8.8%. Earnings per share (EPS) also missed analyst estimates by 2.1%.
Looking ahead, revenue is forecast to grow 70% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden.
Performance of the Swedish Medical Equipment industry.
The company's shares are up 1.2% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for Senzime that we have uncovered.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:SEZI
Senzime
A medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States.
High growth potential with excellent balance sheet.
Market Insights
Community Narratives
